News

Quoin Reports Clinically Meaningful Whole Body Response to QRX003 in Pediatric Netherton Syndrome; Second Patient Cleared for Dosing
Initial pediatric subject shows sustained benefit with QRX003; second patient approved for full-body treatment in ongoing ...
Medscape1d
Netherton Syndrome
A diagnosis of Netherton syndrome was made and the patient was started on antihistamines, emollients, and 10% urea. In our case, the patient presented at age 17 years. The history of his ...
TMCnet5d
Quoin Pharmaceuticals Releases Second Episode of its "Living with Netherton" Series, as part of its ongoing NETHERTON NOW awareness campaign
Quoin’s lead product candidate, QRX003, is currently being evaluated in four clinical trials for the treatment of Netherton Syndrome. The Company’s goal is to develop the first FDA-aproved therapy for ...
Nasdaq21d
Quoin Pharmaceuticals Files Patent Application for QRX003 to Treat Netherton Syndrome and Other Rare Skin Conditions
Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome.
Business Insider21d
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis Third Quoin Patent Application for Netherton Syndrome If Granted Company ...
Seeking Alpha13d
Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second ...
For a majority of Netherton Syndrome patients, the continuous presence of chronically debilitating pruritus is the worst symptom of this disease and it severely impacts their ability to sleep or ...
Quoin announces additional data from Pediatric Netherton Syndrome study
Quoin Pharmaceuticals (QNRX) announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome ...
Morningstar5d
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company’s NETHERTON NOW website ASHBURN ...
Yahoo Finance5d
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
This installment features Norma Coles, a 79-year-old woman whose diagnosis with Netherton Syndrome came decades after she was first evaluated by the condition’s namesake, Dr. Edward Netherton.
Taiwan News4d
Quoin Pharmaceuticals Releases Second Episode of its “Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company’s NETHERTON NOW website ASHBURN, Va., April ...
manilatimes5d
Quoin Pharmaceuticals Releases Second Episode of its "Living with Netherton” Series, as part of its ongoing NETHERTON NOW awareness campaign
Video features 79-year-old Norma Coles, believed to be among the earliest individuals ever evaluated for Netherton Syndrome and is available on the company's NETHERTON NOW website ASHBURN, Va., April ...